US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares MSCI Pacific ex Japan ETF

55.31

-0.1500-0.27%

Post-market: 55.310.00000.00%16:10 EST

Volume:465.41K

Turnover:25.68M

Market Cap:2.09B

PE:6.51

High:55.39

Open:55.05

Low:54.77

Close:55.46

52wk High:56.23

52wk Low:38.44

Shares:37.80M

Float Shares:37.80M

Volume Ratio:0.93

T/O Rate:1.23%

Dividend:1.83

Dividend Rate:3.30%

EPS(TTM):8.50

EPS(LYR):8.50

ROE:15.89%

ROA:2.19%

PB:1.13

PE(LYR):6.51

Loading ...

Overview Company News Filings

Disc Medicine EPP Treatment Fails to Get FDA Accelerated Approval

Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP

Trump Threatens Tariff Hikes as Senior European Parliament Figures Back Using "Anti-Coercion Instrument" Against US

Europe Accuses Trump of Triggering "Dangerous Vicious Cycle," Faces Difficult Choices

'Approval Is Not Possible At This Stage,' EPP Chief Says, Threatening Collapse Of EU-US Trade Deal: 'Must Be Put On Hold'

Benzinga_recent_news

CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies

EU Moves to Weaken Corporate Sustainability Reporting Rules, Signaling Shift in Green Policy

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times

Benzinga_recent_news

Health Canada Extends Review of CLINUVEL’s SCENESSE® for EPP

Buy Rating Affirmed for Disc Medicine Amid Promising Bitopertin Prospects in EPP Treatment

Down 34%, Should You Buy the Dip on BigBear.ai Stock?

Disc Medicine submits NDA to FDA for bitopertin in patients with EPP

CLINUVEL to advance novel pharmaceutical formulations in preclinical program

Fortinet Named a Leader in the 2025 Gartner® Magic Quadrant™ for Hybrid Mesh Firewall

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/EPP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EPP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EPP\",,,,,undefined,":{"symbol":"EPP","market":"US","secType":"STK","nameCN":"iShares MSCI Pacific ex Japan ETF","latestPrice":55.31,"timestamp":1771016400000,"preClose":55.46,"halted":0,"volume":465411,"hourTrading":{"tag":"盘后","latestPrice":55.31,"preClose":55.31,"latestTime":"16:10 EST","volume":2775,"amount":153485.25,"timestamp":1771017004755,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.002704652001442455,"floatShares":37800000,"shares":37800000,"eps":8.495214,"marketStatus":"Market Closed","change":-0.15,"latestTime":"02-13 16:00:00 EST","open":55.05,"high":55.39,"low":54.77,"amount":25675757.2594,"amplitude":0.011179,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":8.495214,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":55.46,"sharesOutstanding":37800000,"nav":55.297928,"aum":2090261678.4,"dividendRate":0.033018,"bidAskSpread":0.000207,"postHourTrading":{"tag":"盘后","latestPrice":55.31,"preClose":55.31,"latestTime":"16:10 EST","volume":2775,"amount":153485.25,"timestamp":1771017004755,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.925278471400081,"impliedVol":0.1885,"impliedVolPercentile":0.9641},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EPP\",,,,,undefined,":{"symbol":"EPP","floatShares":37800000,"roa":"2.19%","roe":"15.89%","lyrEps":8.495214,"volumeRatio":0.925278471400081,"shares":37800000,"dividePrice":1.82622,"high":55.39,"amplitude":0.011179,"preClose":55.46,"low":54.77,"week52Low":38.44,"pbRate":"1.13","psRate":"27.35","week52High":56.23,"institutionHeld":0,"latestPrice":55.31,"eps":8.495214,"divideRate":0.033018,"volume":465411,"delay":0,"ttmEps":8.495214,"open":55.05,"prevYearClose":50.47,"prevWeekClose":54.35,"prevMonthClose":53.59,"prevQuarterClose":50.47,"fiveDayClose":54.35,"twentyDayClose":51.88,"sixtyDayClose":50.35},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EPP\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"EPP","amount":1.045605,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"亚太地区（除日本）ETF-iShares MSCI","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"EPP","amount":0.858764,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"亚太地区（除日本）ETF-iShares MSCI","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"EPP","amount":0.96746,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"亚太地区（除日本）ETF-iShares MSCI","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"EPP","amount":0.70131,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"亚太地区（除日本）ETF-iShares MSCI","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"},{"date":"2023-12-20","symbol":"EPP","amount":0.966028,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"亚太地区（除日本）ETF-iShares MSCI","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EPP\",market:\"US\",,,undefined,":[{"executeDate":"2016-06-22","recordDate":"2016-06-24","paymentDate":"2016-06-28","value":0.661333,"currency":"USD"},{"executeDate":"2016-12-21","recordDate":"2016-12-23","paymentDate":"2016-12-28","value":0.90607,"currency":"USD"},{"executeDate":"2017-06-20","recordDate":"2017-06-22","paymentDate":"2017-06-26","value":0.756156,"currency":"USD"},{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-25","value":0.867553,"currency":"USD"},{"executeDate":"2018-12-18","recordDate":"2018-12-19","paymentDate":"2018-12-24","value":1.166804,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EPP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EPP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611193362","title":"Disc Medicine EPP Treatment Fails to Get FDA Accelerated Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2611193362","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611193362?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:14","pubTimestamp":1771017240,"startTime":"0","endTime":"0","summary":"Disc Medicine received a complete response letter from the Food and Drug Administration denying it accelerated approval of its bitopertin treatment for erythropoietic protoporphyria, a metabolic disorder causing photosensitivity.The FDA said results of the company's ongoing Phase 3 study could serve as evidence to support traditional approval. Topline data from the study is expected in the fourth quarter.Following the trial, Disc would then file a response to the complete response letter and expect an updated FDA ruling by mid-2027.\"We are committed to delivering bitopertin to patients, knowing how critical this potentially disease-modifying therapy is to the EPP community. While our efforts at utilizing expedited pathways to get bitopertin to patients quickly have not come to fruition, we are continuing to pursue all avenues in support of FDA approval,\" said Chief Executive John Quisel.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4582","IRON","BK4139","EPP","LU0053671581.USD"],"gpt_icon":0},{"id":"2611160297","title":"Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP","url":"https://stock-news.laohu8.com/highlight/detail?id=2611160297","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611160297?lang=en_us&edition=fundamental","pubTime":"2026-02-14 04:04","pubTimestamp":1771013040,"startTime":"0","endTime":"0","summary":"FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use of ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/13/3238299/0/en/Disc-Medicine-Receives-Complete-Response-Letter-from-FDA-for-Bitopertin-for-the-Treatment-of-EPP.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0757428866.USD","IE00BFMHRM44.USD","IRON","LU0128526141.USD","BK4582","BK4121","EPP","LU0390134368.USD","BK4588","LU1815336091.USD","LU0029874061.USD","BK4530","BK4585","LU0053671581.USD","CRL"],"gpt_icon":0},{"id":"1192819949","title":"Trump Threatens Tariff Hikes as Senior European Parliament Figures Back Using \"Anti-Coercion Instrument\" Against US","url":"https://stock-news.laohu8.com/highlight/detail?id=1192819949","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192819949?lang=en_us&edition=fundamental","pubTime":"2026-01-18 15:40","pubTimestamp":1768722048,"startTime":"0","endTime":"0","summary":"Investing decisions should be based on the research reports of Golden麒麟 analysts, which are authoritative, professional, timely, and comprehensive, helping you uncover potential thematic...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"9f41170e7d283abb71ac1549cfeffc05","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FESXmain","EPP","BK4582","FSXEmain","BK4113","ACI","SINA"],"gpt_icon":0},{"id":"1163241417","title":"Europe Accuses Trump of Triggering \"Dangerous Vicious Cycle,\" Faces Difficult Choices","url":"https://stock-news.laohu8.com/highlight/detail?id=1163241417","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163241417?lang=en_us&edition=fundamental","pubTime":"2026-01-18 14:30","pubTimestamp":1768717845,"startTime":"0","endTime":"0","summary":"On the 17th, US President Donald Trump announced on social media that the United States would impose an additional 10% tariff on goods imported from Denmark, Norway, Sweden, France, Germany, the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"9f41170e7d283abb71ac1549cfeffc05","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPP","BK4582"],"gpt_icon":0},{"id":"2604922008","title":"'Approval Is Not Possible At This Stage,' EPP Chief Says, Threatening Collapse Of EU-US Trade Deal: 'Must Be Put On Hold'","url":"https://stock-news.laohu8.com/highlight/detail?id=2604922008","media":"Benzinga_recent_news","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604922008?lang=en_us&edition=fundamental","pubTime":"2026-01-18 13:06","pubTimestamp":1768712760,"startTime":"0","endTime":"0","summary":"EU lawmakers to halt approval of EU-US trade deal after Trump threatens tariffs on countries backing Greenland in dispute with Washington.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/18/Washington--February-22--2025-President-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/18/Washington--February-22--2025-President-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/politics/26/01/49984678/approval-is-not-possible-at-this-stage-epp-chief-says-threatening-collapse-of-eu-us-trade-deal-must-be-put-on-hold","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/politics/26/01/49984678/approval-is-not-possible-at-this-stage-epp-chief-says-threatening-collapse-of-eu-us-trade-deal-must-be-put-on-hold","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SSI","EPP","BK4582","BK4156"],"gpt_icon":0},{"id":"2589388874","title":"CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2589388874","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589388874?lang=en_us&edition=fundamental","pubTime":"2025-12-08 10:37","pubTimestamp":1765161420,"startTime":"0","endTime":"0","summary":"CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies   CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies   CLINUVEL expands Singapore R","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201174/0/en/CLINUVEL-expands-Singapore-RD-I-Centre-to-pioneer-next-generation-peptide-therapies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4582","EPP"],"gpt_icon":0},{"id":"1182813551","title":"EU Moves to Weaken Corporate Sustainability Reporting Rules, Signaling Shift in Green Policy","url":"https://stock-news.laohu8.com/highlight/detail?id=1182813551","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182813551?lang=en_us&edition=fundamental","pubTime":"2025-11-14 08:42","pubTimestamp":1763080936,"startTime":"0","endTime":"0","summary":"A vote in the European Parliament to relax corporate environmental, social, and governance (ESG) reporting obligations is being interpreted as a strong signal that the EU is shifting its policy focus...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4582","ESG","EPP"],"gpt_icon":0},{"id":"2576505986","title":"FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times","url":"https://stock-news.laohu8.com/highlight/detail?id=2576505986","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576505986?lang=en_us&edition=fundamental","pubTime":"2025-10-17 22:03","pubTimestamp":1760709780,"startTime":"0","endTime":"0","summary":"The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/17/lab--Medical-Hospital-Research-Laborator.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/17/lab--Medical-Hospital-Research-Laborator.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/25/10/48275103/fda-unveils-first-experimental-drugs-under-fast-track-voucher-plan-to-cut-drug-review-times","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/10/48275103/fda-unveils-first-experimental-drugs-under-fast-track-voucher-plan-to-cut-drug-review-times","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0823416689.USD","BK4139","FAST","IRON","USAW.SI","LU2362541513.USD","IE00BFXG0V08.USD","RVMD","LU2023250504.SGD","LU2468319806.SGD","LU2362540622.SGD","NQmain","BK4585","BK4588","TSYW.SI","LU0058720904.USD","QID","LU0823434740.USD","BK4007","BK4567","SNY","LU2089984988.USD","REGN","LU2106854487.HKD","ACHV","SQQQ","LU2237438978.USD","USJW.SI","LU0889565916.HKD","IE00B5TLWC47.USD","IE00BFXG1179.USD","XLP","EPP","LU0823434583.USD","LU1917777945.USD","LU0320765992.SGD","NVIW.SI","IE00BYQQ9H92.USD","PSQ","LU1974910355.USD","LU0109394709.USD","LU0289739699.SGD","LU0053666078.USD","LU0882574055.USD","QLD",".IXIC","MNQmain","TQQQ","BK4582"],"gpt_icon":1},{"id":"2575760584","title":"Health Canada Extends Review of CLINUVEL’s SCENESSE® for EPP","url":"https://stock-news.laohu8.com/highlight/detail?id=2575760584","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575760584?lang=en_us&edition=fundamental","pubTime":"2025-10-16 10:47","pubTimestamp":1760582871,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an update. CLINUVEL Pharmaceuticals announced that Health Canada has requested additional time...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/health-canada-extends-review-of-clinuvels-scenesse-for-epp?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/health-canada-extends-review-of-clinuvels-scenesse-for-epp?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4582","EPP"],"gpt_icon":0},{"id":"2573673819","title":"Buy Rating Affirmed for Disc Medicine Amid Promising Bitopertin Prospects in EPP Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2573673819","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573673819?lang=en_us&edition=fundamental","pubTime":"2025-10-06 17:15","pubTimestamp":1759742132,"startTime":"0","endTime":"0","summary":"Sean Laaman, an analyst from Morgan Stanley, maintained the Buy rating on Disc Medicine. The associated price target remains the same with $90.00. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-disc-medicine-amid-promising-bitopertin-prospects-in-epp-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-disc-medicine-amid-promising-bitopertin-prospects-in-epp-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRON","EPP"],"gpt_icon":0},{"id":"2572588508","title":"Down 34%, Should You Buy the Dip on BigBear.ai Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2572588508","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572588508?lang=en_us&edition=fundamental","pubTime":"2025-10-03 16:32","pubTimestamp":1759480320,"startTime":"0","endTime":"0","summary":"This AI software specialist's recent results haven't been great, but it is operating in a lucrative market.","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F835618%2Fperson-folded-hands-computer.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F835618%2Fperson-folded-hands-computer.jpg&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/investing/2025/10/03/down-34-should-you-buy-the-dip-on-bigbearai-stock/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/10/03/down-34-should-you-buy-the-dip-on-bigbearai-stock/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["EPP","BK4023","BK4551","BK4582","BK4528","BK4543","BK4585","BK4587","BK4588"],"gpt_icon":1},{"id":"2571340635","title":"Disc Medicine submits NDA to FDA for bitopertin in patients with EPP","url":"https://stock-news.laohu8.com/highlight/detail?id=2571340635","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571340635?lang=en_us&edition=fundamental","pubTime":"2025-09-30 20:40","pubTimestamp":1759236051,"startTime":"0","endTime":"0","summary":"Disc Medicine (IRON) announced the submission of a New Drug Application to the U.S. Food and Drug Administration for bitopertin for patients aged 1...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/disc-medicine-submits-nda-to-fda-for-bitopertin-in-patients-with-epp-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/disc-medicine-submits-nda-to-fda-for-bitopertin-in-patients-with-epp-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPP","BK4582","BK4139","IRON"],"gpt_icon":0},{"id":"2571872468","title":"CLINUVEL to advance novel pharmaceutical formulations in preclinical program","url":"https://stock-news.laohu8.com/highlight/detail?id=2571872468","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571872468?lang=en_us&edition=fundamental","pubTime":"2025-09-29 10:56","pubTimestamp":1759114560,"startTime":"0","endTime":"0","summary":"Next generation sustained-release formulations for a variety of peptidesExecutive summary first biocompatible pharmaceutical formulations progress to preclinical modelsnew sustained-release drug deliv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/29/3157395/0/en/CLINUVEL-to-advance-novel-pharmaceutical-formulations-in-preclinical-program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPP","BK4582"],"gpt_icon":0},{"id":"2562728655","title":"Fortinet Named a Leader in the 2025 Gartner® Magic Quadrant™ for Hybrid Mesh Firewall","url":"https://stock-news.laohu8.com/highlight/detail?id=2562728655","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562728655?lang=en_us&edition=fundamental","pubTime":"2025-08-27 23:03","pubTimestamp":1756306980,"startTime":"0","endTime":"0","summary":"Fortinet placed highest in Ability to ExecuteSUNNYVALE, Calif., Aug.  27, 2025  (GLOBE NEWSWIRE) --  News SummaryFortinet (NASDAQ: FTNT), the global cybersecurity leader driving the convergence of net","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/27/3140187/0/en/Fortinet-Named-a-Leader-in-the-2025-Gartner-Magic-Quadrant-for-Hybrid-Mesh-Firewall.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","FTNT","LU0079474960.USD","LU1917777945.USD","LU1974910355.USD","LU2023250843.SGD","LU2286300806.USD","BK4097","LU2106854487.HKD","LU0170899867.USD","BK4585","LU2023250504.SGD","BK4588","BK4582","IE0008368304.USD","BK4560","EPP","LU0348723411.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}